First FDA pregnancy-approved Pertussis vaccine to protect newborns
European Pharmaceutical Review
OCTOBER 10, 2022
The FDA initially approved Boostrix in 2005 as a vaccine to protect against Tdap in patients from 10 years old to 18. Side effect data related to those given the non-US variation during pregnancy was consistent with data for individuals who were given the non-US formulation post labour.
Let's personalize your content